OncoRx (US) signs up Response Biomedical's white cell monitor
This article was originally published in Clinica
OncoRx (US) will distribute and sell Response Biomedical's (Canada) point-of-care granulocyte monitor once it has been approved in North America. Under the deal, OncoRx will sell the hand-held monitor and associated disposables for oncology outpatient use in Canada and the US. Response will receive a $750,000 milestone payment when the device is approved by the FDA.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.